This isn't the first approval of a Genmab-developed drug, nor is it the first cancer drug that the Danish biotech company is behind. Nonetheless, the approval of tisotumab vedotin, under the commercial name Tivdak, by the US Food and Drug Administration (FDA) is an important stepping stone on the path forward, says Søren Løntoft Hansen, senior analyst at Sydbank.
"The approval of Tivdak is very positive in the way it contributes to the gradually growing portfolio of approved medicines coming from Genmab laboratories, which emphasizes that Genmab is now more than just Darzalex," he tells MedWatch.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Lundbeck chairman demands change: "We can't live with this"
Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.
Coloplast could win big on Polish reimbursement changes
The Polish Ministry of Health has increased the reimbursement amount for hydrophilic catheters, which Coloplast supplies. The Danish medtech company calls the new scheme a "breakthrough."
Several positive elements in Eli Lilly Q3 report, says analyst
.jpg)
An analyst at Sydbank thinks that Eli Lilly's third quarter report includes a number of positive elements, and emphasizes that this could also be good news for competitor Novo Nordisk.
Eli Lilly upgrades earnings per share guidance
On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.
Cloud computing saves money and cuts carbon emissions at Novo Nordisk
Integrating cloud solutions has helped with Novo Nordisk's sustainable transition, Danish media reports.
Head of Engineering, Syntese 
Senior Clinical Trial Manager 
VP, Head of CMC Pharmaceutical and Device Development 
SAP Process Supporter for Operations at ALK 
CMC Project Manager 
Senior Programmer at Genmab 
KLIFO is looking for a talented and committed Pharmacovigilance Associate based in Denmark 
Jr. Software Developer, Cardiac Applications – Medical Devices, DK 
Global Product Manager 
Clinical Documentation Specialist 
GxP QA Compliance Manager for Quality Assurance 
Key Account Manager – Lab & Diagnostic 
Nordic Field Sales Manager 
Application Manager (GxP Systems) - Zealand Pharma 
Regulatory Science Specialist